July 1, 2024Open Access

The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes

Key Points

Key points are not available for this paper at this time.

Abstract

We examined the impact of a co-diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D) on patient outcomes.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Riley et al. (Mon,) studied this question.

synapsesocial.com/papers/68e61ca0b6db6435875aebdb https://doi.org/https://doi.org/10.1111/liv.16016

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study2024 · 151 citations
2The Impact of Diabetes and Glucose-Lowering Therapies on Hepatocellular Carcinoma Incidence and Overall Survival2022 · 11 citations
3Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study2015 · 2,115 citations
4Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis2018 · 124 citations
5Prevalence of and Risk Factors for Nonalcoholic Fatty Liver Disease: The Dionysos Nutrition and Liver Study * #2005 · 1,268 citations

Bookmark

View Full Paper